Gordana Raca

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4081823/publications.pdf

Version: 2024-02-01

35 papers	1,409 citations	687363 13 h-index	454955 30 g-index
38 all docs	38 docs citations	38 times ranked	2906 citing authors

#	Article	IF	Citations
1	A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nature Genetics, 2020, 52, 448-457.	21.4	104
2	Diagnostic testing for uniparental disomy: a points to consider statement from the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 1133-1141.	2.4	89
3	Myeloid lineage switch following chimeric antigen receptor Tâ€cell therapy in a patient with TCF3â€ZNF384 fusionâ€positive Bâ€lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27265.	1.5	67
4	OncoKids. Journal of Molecular Diagnostics, 2018, 20, 765-776.	2.8	58
5	A semiautomated whole-exome sequencing workflow leads to increased diagnostic yield and identification of novel candidate variants. Journal of Physical Education and Sports Management, 2019, 5, a003756.	1.2	41
6	Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). Genetics in Medicine, 2019, 21, 1903-1916.	2.4	39
7	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics, 2018, 228-229, 197-217.	0.4	25
8	Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genetics, 2018, 228-229, 218-235.	0.4	21
9	Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino childrenâ€”a novel health disparity. Leukemia, 2021, 35, 2399-2402.	7.2	19
10	Standard operating procedure for curation and clinical interpretation of variants in cancer. Genome Medicine, 2019, 11, 76.	8.2	16
11	Adapting crowdsourced clinical cancer curation in CIViC to the ClinGen minimum variant level data communityâ€driven standards. Human Mutation, 2018, 39, 1721-1732.	2.5	15
12	Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genetics, 2020, 243, 52-72.	0.4	14
13	Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia. Blood, 2021, 138, 199-202.	1.4	8
14	A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia. Cancer Genetics, 2017, 216-217, 91-99.	0.4	6
15	A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies. Cancer Genetics, 2021, 254-255, 25-33.	0.4	6
16	Dilated cardiomyopathy in a patient with autosomal dominant EEF1A2-related neurodevelopmental disorder. European Journal of Medical Genetics, 2021, 64, 104121.	1.3	5
17	Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions. Cancer Genetics, 2022, 264-265, 50-59.	0.4	5
18	Response to Maya et al.. Genetics in Medicine, 2020, 22, 1278-1279.	2.4	4

#	Article	IF	Citations
19	Primary Knee Intra-articular Synovial Sarcoma in Pediatric and Adolescent Patients. Pediatric and Developmental Pathology, 2021, 24, 159-163.	1.0	3
20	Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Archives of Pathology and Laboratory Medicine, 2021, 145, 176-190.	2.5	3
21	Characterization of PAX5 Intragenic Tandem Multiplication in Pediatric B-Lymphoblastic Leukemia by Optical Genome Mapping. Blood Advances, 2022, , .	5.2	3
22	A community approach to the cancer-variant-interpretation bottleneck. Nature Cancer, 2022, 3, 522-525.	13.2	3
23	Pediatric Metastatic Hepatoblastoma With an ARID1A Mutation and Rhabdoid Cells. International Journal of Surgical Pathology, 2022, 30, 307-312.	0.8	2
24	Congenital B-lymphoblastic leukemia with a cryptic MLL rearrangement and post-treatment evolution to mixed phenotype acute leukemia. Leukemia Research Reports, 2016, 6, 29-32.	0.4	1
25	Response to Mounts and Besser. Genetics in Medicine, 2021, 23, 240-242.	2.4	1
26	PLAG1 Immunohistochemical Staining Is a Surrogate Marker for PLAG1 Fusions in Lipoblastomas. Pediatric and Developmental Pathology, 2021, , 109352662110433.	1.0	1
27	Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia, 2021, 35, 3611-3612.	7.2	1
28	insufficient for pathogenesis. Cancer Genetics, 2022, 260-261, 37-40.	0.4	1
29	Primary Adrenal Malignant Rhabdoid Tumor in a 14-Year-Old Female: A Case Report and Literature Review. International Journal of Surgical Pathology, 2022, 30, 172-176.	0.8	0
30	Abstract 210: Advancing knowledgebase representation of pediatric cancer variants through ClinGen/CIViC collaboration. , 2021, , .		0
31	Abstract 449: A standard operating procedure for the curation of gene fusions. , 2021, , .		0
32	Whole genome SNP arrays for best practice for detection of diagnostic, prognostic and therapy related copy number changes and copy neutral-loss of heterozygosity across solid tumors and hematologic malignancies.. Journal of Clinical Oncology, 2020, 38, e15575-e15575.	1.6	0
33	Efficacy and Safety of FLAG-Ida As Frontline Therapy in a Pediatric AML Population: A Single Institution Experience. Blood, 2021, 138, 2342-2342.	1.4	0
34	Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT). Blood, 2021, 138, 4387-4387.	1.4	0
35	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). Blood, 2020, 136, 23-23.	1.4	0